Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.4450
+0.0110 (2.53%)
At close: Aug 13, 2025, 4:00 PM
0.4401
-0.0049 (-1.10%)
Pre-market: Aug 14, 2025, 9:03 AM EDT
Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD.
The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | George Lasezkay |
Contact Details
Address: 900 North Point Parkway, Suite 200 Alpharetta, Georgia 30005 United States | |
| Phone | 678 270 3631 |
| Website | clearsidebio.com |
Stock Details
| Ticker Symbol | CLSD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001539029 |
| CUSIP Number | 185063104 |
| ISIN Number | US1850631045 |
| Employer ID | 45-2437375 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | Director and Principal Executive Officer |
| Charles A. Deignan | Principal Financial Officer and Principal Accounting Officer |
| Jenny R. Kobin | Head of Investor Relations |
| Rick McElheny | Senior Vice President of Corporate Development and Alliance Management |
| Rafael V. Andino | Senior Vice President of Engineering and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 25, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 17, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 18, 2025 | ARS | Filing |
| Apr 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |